Full-Time

Director of Scientific Affairs

Ossium Health

Ossium Health

51-200 employees

Stem cell therapies from deceased donors

Compensation Overview

$200k - $275k/yr

+ Stock Options + 401(k) Matching

No H1B Sponsorship

San Francisco, CA, USA

Hybrid

Hybrid schedule: in-office Mon–Thu, remote Fri; travel 15–30% for meetings and sites.

Category
Biology & Biotech (2)
,
Required Skills
Branding/Brand Strategy
biostatistics
Data Analysis
Requirements
  • MD/PhD in a life science/biomedical discipline with strong clinical experience
  • 5+ years of industry experience
  • Proven ability to collaborate, partner, and influence across multiple functions and levels of leadership
  • Demonstrated experience with manuscript and abstract writing and post hoc data analyses
  • Experience working with Medical Science Liaisons and providing medical/scientific support to commercial teams
  • Proven agility and adaptability in a fast-paced, results-driven startup environment
  • Excellent written, verbal, and presentation communication skills
  • Understanding of biostatistical concepts to analyze clinical trial data
  • Comfortable with travel from 15% - 30%
  • Position based in San Francisco with hybrid schedule Monday-Thursday in office and Friday remote
  • Qualified candidates must be legally authorized to be employed in the United States; Ossium unable to provide sponsorship for employment visa status (eg, H-1B or TN status) for this position
Responsibilities
  • Drive scientific communications internally and externally, including data dissemination, educational initiatives, and guideline/value-proposition development
  • Assist with strategic publication planning and writing/preparing manuscripts, abstracts, and presentations
  • Collaborate closely with Medical Science Liaisons to generate, synthesize, and communicate scientific insights from field interactions
  • Assist with initiating and maintaining relationships with transplant medical doctors and Principal Investigators
  • Lead evidence-generation initiatives (clinical, secondary analyses, real-world evidence) to enhance understanding of therapeutic benefit and value
  • Serve as medical reviewer on the Promotional Review Committee and ensure scientific accuracy and compliance of promotional materials
  • Support congress planning and key opinion leader engagement efforts in partnership with the Medical Science Liaison team
  • Provide strategic medical and scientific input into brand strategies, supporting product launches and ongoing commercialization activities
  • Provide medical guidance to clinical operations teams and support cross-functional collaboration with Commercial, Market Access, Regulatory, and Clinical Development
  • Generate and maintain proactive educational content to support internal training and external stakeholder engagement
  • Travel as needed to scientific meetings, clinical sites, or investigator interactions
  • In the first six months, work on supporting authorship and submission of manuscripts and abstracts to major scientific meetings (e.g., ASH, TANDEM)
  • Partner with field and commercial teams to deliver clinical and scientific support for product-launch activities for HPC, Marrow
  • Establish relationships with individual sites and Principal Investigators to initiate evidence generation projects
Desired Qualifications
  • Scientific or clinical expertise in hematologic malignancies, hematopoietic cell transplantation (Hematopoietic cell transplantation) or cell therapy
  • Experience supporting product launch
  • Background in rare disease or a specialized therapeutic indication (e.g., bone marrow transplantation)
  • Experience in clinical development or protocol support

Ossium Health develops cell therapies using stem cells from deceased donors to treat blood diseases and immune disorders, reduce organ transplant rejection, and address orthopedic conditions. Therapies are created through research, clinical trials, and partnerships, and distributed via collaborations and licensing to bring proprietary products to patients. The company differentiates itself by leveraging deceased-donor stem cells and close ties with organ procurement networks, building a portfolio across hematology, immunology, transplantation, and orthopedics. The goal is to make effective donor-derived cell therapies more accessible to improve health, vitality, and longevity.

Company Size

51-200

Company Stage

Series C

Total Funding

$134.9M

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • PRESERVE I first-four-patient data presented February 2026 demonstrates safety feasibility.
  • HOPE Program expands access beyond trial to ineligible acute leukemia patients.
  • OPO partnerships with LifeGift since 2017 establish reliable donor supply chain.

What critics are saying

  • Only ~34,000 US organ donors annually limits addressable market to 9,000 patients.
  • PRESERVE I enrolled only 12 patients across five centers; slow enrollment threatens regulatory pathway.
  • Delayed GVHD or graft failure in later cohorts triggers FDA clinical hold.

What makes Ossium Health unique

  • Only off-the-shelf bone marrow bank sourced from deceased organ donors.
  • Eliminates living donor search delays; cryopreserved inventory available on-demand.
  • FDA-registered Indianapolis facility with 34,000 SF cleanrooms and CLIA certification.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Ossium Health who can refer or advise you

Benefits

Medical, dental and vision coverage

401(k) Company Match

Stock Options

Unlimited Paid Time Off

Employer paid life insurance and long term disability

Gym membership/recreational sports reimbursements

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

1%
Weston, Inc.
Apr 20th, 2026
Ossium Health's Indianapolis facility reflects the rise of life sciences real estate.

Ossium Health's Indianapolis facility reflects the rise of life sciences real estate. April 20, 2026 Indianapolis is home to Ossium Health, a biotech company which operates the world's first bone marrow bank for the treatment of diseases of the blood and immune systems. Bone marrow banking is the process of collecting, processing, and storing bone marrow stem cells so they are available for medical treatment when needed, rather than relying on live donors at the time of illness. Govenor Mike Braun toured Ossium's nearly 34,000 SF production facility at 5742 W 74th Street last week after recently announcing $1B in incentives for life sciences. The visit highlighted Ossium's innovative work and emphasized Indianapolis' potential for becoming the Silicon Valley for life sciences. The building includes multiple cleanrooms, research and development laboratories, bulk storage areas, and office space for a growing team of scientists, production specialists, and quality personnel. This type of buildout underscores a key trend in industrial real estate, which is that life sciences users require highly customized spaces that support strict regulatory standards, advanced infrastructure, and long-term scalability. Facilities like Ossium's push far beyond traditional warehouse or flex space, blending elements of industrial, lab, and office environments into a single, specialized footprint. Indianapolis continues to strengthen its position as a growing hub for life sciences and advanced manufacturing, and Weston Inc. is pleased to have Ossium as a tenant. Ask Weston Inc. any questions. Its representatives are available to help answer your questions.

Ossium Health
Mar 3rd, 2026
Forbes Selects Ossium as One of America's Best Startup Employers

Forbes selects Ossium as one of America's Best Startup Employers. For the second time in three years, Ossium Health has been named to Forbes' list of America's Best Startup Employers. This annual list highlights a select group of U.S. startups that demonstrate excellence in employee satisfaction, employer reputation, and organizational growth - criteria that reflect not only business performance, but the strength of a company's culture and its ability to attract and retain exceptional talent. At Ossium, its work is driven by a singular mission: to improve the health, vitality, and longevity of human beings through bioengineering. Achieving this mission requires bringing together individuals who are deeply committed to scientific innovation and motivated by the opportunity to make a meaningful impact on patients facing serious and life-threatening conditions. Being recognized by Forbes underscores the environment ossiumhealth.com has built: one where talented individuals can do their best work in pursuit of transformative medical advances. Its team's dedication extends beyond day-to-day responsibilities. It is reflected in the care with which ossiumhealth.com develop and deliver novel cell-based therapies, the rigor of its clinical and research programs, and the shared sense of purpose that unites its organization. ossiumhealth.com believe that fostering a mission-driven, collaborative, and supportive workplace is essential to advancing breakthroughs that save lives. "This recognition is a direct reflection of our team and the culture we've built together," said Kevin Caldwell, CEO, President & Co-founder of Ossium Health. "We've assembled a group of people who are not only exceptionally talented, but deeply committed to our mission. Their passion, integrity, and persistence are what enable us to pursue ambitious goals in bioengineering and deliver meaningful impact for patients. We're honored to be recognized alongside other outstanding startups and remain focused on building an organization where people can do the most important work of their careers." Ossium is actively growing and looking for exceptional individuals to join its team. If you're motivated by the opportunity to help pioneer the future of bioengineering and make a meaningful difference for patients, ossiumhealth.com encourage you to explore open roles at ossiumhealth.com/careers. ossiumhealth.com is grateful to its entire team for their contributions and proud to be included among this year's Best Startup Employers. Join its team. At Ossium, ossiumhealth.com is always looking for talented, mission-driven people.

HealthTech HotSpot
Jan 23rd, 2026
Ossium Health to Present New Clinical Data from PRESERVE I Study at the 2026 Tandem Meetings

Ossium Health to present new clinical data from PRESERVE I study at the 2026 Tandem Meetings. January 23rd, 2026 | Business Wire SAN FRANCISCO - (BUSINESS WIRE) - Ossium Health, a clinical-stage biotechnology company pioneering off-the-shelf bone marrow therapies derived from deceased organ donors, today announced it will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings taking place on February 4-7, 2026 in Salt Lake City, UT. Ossium will deliver one oral presentation and three poster presentations highlighting clinical experience with its cryopreserved, donor-derived bone marrow platform. The featured oral presentation will showcase first-in-human clinical data from the first four patients treated in the PRESERVE I study, marking an important milestone in the advancement of off-the-shelf bone marrow transplantation. Ossium's Chief Medical Officer, Dr. Sagar Munjal, will present the study's encouraging preliminary data, which demonstrate the safety and feasibility of transplanting bone marrow derived from deceased donors. Additional poster presentations underscore key advantages of Ossium's off-the-shelf bone marrow platform, including its ability to provide immediate graft availability in urgent scenarios when a living donor becomes unavailable, as well as its potential to reduce relapse risk. Title: A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies Presenter: Sagar Munjal, MD, Chief Medical Officer & Senior Vice President, Ossium Health Presentation ID: 89 Date and Time: Saturday, Feb 7, 11:30 AM - 11:45 AM MST Location: Ballroom J Title: Demonstrating the Feasibility of Refreezing Previously Cryopreserved Bone Marrow Following Reprocessing Poster ID: 296 Date and Time: Thursday, Feb 5, 6:30 PM - 8:00 PM MST Location: Hall AB "These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow," said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. "We look forward to sharing insights from PRESERVE I and related clinical experience with the transplant community at Tandem." The company will also exhibit at Booth #106, where attendees can learn more about Ossium's organ donor-derived bone marrow banking platform and clinical studies. The Tandem Meetings are jointly hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) and represent one of the premier global forums for advances in hematopoietic cell transplantation and cellular therapy. About Ossium Health Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health's manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com. Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth. Jane Griffin Ossium Health, Inc. 415-513-5535 [email protected] January 23rd, 2026

Ossium Health
Feb 11th, 2025
Ossium to Exhibit at Tandem in Honolulu

ossiumhealth.com is excited to announce that Ossium will be exhibiting at the 2025 Transplantation & Cellular Therapy (Tandem) Meetings of ASTCT and CIBMTR, taking place from February 12-15 in Honolulu, Hawaii.

Ossium Health
Sep 12th, 2024
Ossium Ranks No. 56 on Fast Company's 100 Best Workplaces for Innovators

Ossium ranks No. 56 on Fast Company's 100 Best Workplaces for Innovators.